Needham & Company maintains a "buy" rating on Rocket Pharmaceuticals with a $52 price target.

Needham & Company has maintained a "buy" rating on Rocket Pharmaceuticals (NASDAQ: RCKT) with a $52 price target, amid positive feedback from other analysts. The average rating for the company is "Moderate Buy" at a consensus target of $51.75. Meanwhile, Rocket Lab USA (NASDAQ: RKLB) shares reached a 52-week high after Citigroup raised its price target to $13, with increasing support from institutional investors, who own 71.78% of the stock.

November 08, 2024
5 Articles